Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Improvement of Postoperative Immunosuppression in Patients Receiving Coronary Artery Bypass Grafting by TEAS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02933996
Recruitment Status : Completed
First Posted : October 14, 2016
Last Update Posted : May 27, 2020
Sponsor:
Collaborator:
Guangdong Provincial People's Hospital
Information provided by (Responsible Party):
Jiangang Song, ShuGuang Hospital

Brief Summary:
The coronary artery bypass grafting (CABG) is a surgery to relieve angina and reduce mortality of coronary heart disease. However, the patient is more prone to have immunosuppression after the surgery, causing secondary infection, and it is closely correlated to the occurrence and progress of tumor after surgery. More and more studies revealed that needle puncture was able to effectively regulate the function of immune system. However, its perioperative application is unclear. Therefore, this clinical study is aimed to evaluate whether the effect of transcutaneous acupoint electric stimulation (TEAS) on improvement of immunosuppression of patients after receiving CABG.

Condition or disease Intervention/treatment Phase
Immunosuppression Device: TEAS+GA group Device: Sham TEAS+GA group Not Applicable

Detailed Description:

This clinical study was a single-center clinical trial. The 88 patients scheduled to receive CABG under CPB were randomized into 2 groups: the group of TEAS, and the group of transcutaneous acupoint pseudo - electric stimulation (Sham TEAS). Monocytic HLA-DR expression serves as a primary endpoint, and other laboratory parameters (e.g. IL-6, IL-10) and clinical outcomes (e.g. postoperative infectious complications, ICU stay time, and mortality) as the secondary endpoints. In addition, some immune indicators, such as high mobility group protein 1 (HMGB1) and regulatory T cell (Treg), possibly related to the mechanism of TEAS, will also be measured.

This study is a preliminary, mono-center, double-blind, randomized and controlled clinical trial (number of sample, n=88) to explore the effects of TEAS therapy on improvement of postoperative immunosuppression indicated by diminished HLA-DR expression of patients receiving CABG (Fig. 1). The trial will be commenced after ethical approval has been obtained from the Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. All study-related procedures will be performed only after subjects have given their written informed consent. The trial is designed following the Consolidated Standards of Reporting Trials (CONSORT) guidelines, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist (Additional file 1), and Standards for Reporting Interventions in Controlled Trials of Acupuncture (STRICTA) recommendations.

We calculate the sample size from the pilot study in our hospital based on the primary outcome Human leukocyte antigen of monocyte (mHLA-DR). In the study, the expression of mHLA-DR three days after surgery was (36.17±5.42) % in the TEAS group and (27.33±3.50) % in the Sham TEAS group, with a power of 80% and 5% Type I error rate. Assuming that the dropout rate to be 10%, 88 patients (n=44 for each group) are needed.

Patients will be recruited from the department of Thoracic and Cardiovascular surgery, at Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Potentially eligible subjects who have scheduled for CABG under CPB for coronary diseases will be invited to participate. Patients will be referred from a cardiothoracic surgeon, and then a research assistant will approach the subjects in the general ward pre operation. Patients will be screened and consented for the study. Following the consent, eligible participants will be block randomized into two groups: ⑴ TEAS group (n=44) and ⑵ sham TEAS group (n=44). All patients will conduct a standard operative procedure and postoperative analgesia management. The patients of TEAS group will receive TEAS therapy in perioperative period, and the Sham TEAS will not be performed to receive electrical stimulation sensation in perioperative period. Assessments will be conducted during the perioperative period until 30 days after surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Improvement of Postoperative Immunosuppression in Patients Receiving Coronary Artery Bypass Grafting by Transcutaneous Electrical Acupoint Stimulation: Study Protocol for a Double-blind Randomized Controlled Trial
Actual Study Start Date : December 1, 2017
Actual Primary Completion Date : February 29, 2020
Actual Study Completion Date : March 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TEAS+GA group

The patients of TEAS+GA group will receive TEAS therapy in perioperative period.

GA: general anesthesia

Device: TEAS+GA group
The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.

Device: Sham TEAS+GA group
No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.

Sham Comparator: Sham TEAS+GA group
The patients of Sham TEAS+GA will receive none TEAS in perioperative period.
Device: TEAS+GA group
The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.

Device: Sham TEAS+GA group
No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.




Primary Outcome Measures :
  1. Proportion of mHLA-DR positive cell [ Time Frame: day before surgery, Day 1 after surgery (one day after surgery), Day 3 after surgery (3 days after surgery), and Day 5 after surgery (5 days after surgery). ]
    Human leukocyte antigen of monocyte (mHLA-DR)


Secondary Outcome Measures :
  1. Content of serum IL-6 [ Time Frame: One day before surgery, Day 1, 3 and 5 after surgery ]
    interleukin-6 (IL-6)

  2. Content of serum CRP [ Time Frame: One day before surgery, Day 1, 3 and 5 after surgery ]
    reactive protein C (CRP)

  3. Rate of secondary infection [ Time Frame: Within 7 days after surgery ]
    observe the incidence of incision infection, lung infection, hematogenous infection and indwelled catheter infection after the surgery



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  1. Aged 18-75 years, male and female;
  2. Patients diagnosed as coronary disease, scheduled to receive CABG;
  3. BMI: 18.5kg/m2<BMI≤30kg/m2;
  4. Graded as I-III by American Standards Association(ASA);
  5. Patients firstly receiving CABG under extracorporeal circulation.

Exclusion Criteria

  1. Presence of surgical incision or scar at Zusanli acupoint (ST36) /Shenshu (BL23) acupoint;
  2. Patients with local skin infection at acupoint;
  3. Patients with nerve injury on upper or lower limbs;
  4. Patients with history of spinal surgery;
  5. Patients who have participated in other clinical trial in recent 4 weeks;
  6. Patients using pacemaker;
  7. Patients combined with pain before surgery who are using central analgesic drug or drug abuser (e.g., opioid) and dependent user;
  8. Patients combined with severe central nervous system disease or severe mental disease;
  9. Patients with alcoholic history;
  10. Patients who have received emergent coronary bypass operation due to acute myocardial infarction.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02933996


Locations
Layout table for location information
China, Shanghai
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai, China, 201203
Sponsors and Collaborators
ShuGuang Hospital
Guangdong Provincial People's Hospital
Investigators
Layout table for investigator information
Principal Investigator: Jianggang Song, M.D. Shuguang Hospital Affiliated to Shanghai University of TCM
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jiangang Song, deputy director of anesthesia, ShuGuang Hospital
ClinicalTrials.gov Identifier: NCT02933996    
Other Study ID Numbers: 14401932600
First Posted: October 14, 2016    Key Record Dates
Last Update Posted: May 27, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Study Protocol will be shared with other researchers.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: The data will become available with 6 months of study completion.
Access Criteria: Data access requests will be reviewed by an extemal independent Review Panel. Requestors will be required to sign a Data Access Agreement.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Jiangang Song, ShuGuang Hospital:
immunosuppression
cardiac surgery
TEAS(Transcutaneous electrical acupoint stimulation)
postoperative